DHEA for Menopause: What Actually Works, What Doesn't, and What Each Form Costs

DHEA for menopause is not one treatment. The strongest evidence is for prescription vaginal prasterone (Intrarosa, 6.5 mg nightly), FDA-approved for moderate-to-severe painful sex caused by menopausal vaginal changes. Oral DHEA — whether sold over the counter or prescribed as a compounded capsule — is not FDA-approved for any menopause symptom. Intrarosa prescribing information

Affiliate disclosure: The HRT Index has affiliate relationships with Winona and Midi Health. This guide contains no direct provider affiliate links.

That's the answer. Here's the part almost nobody tells you: the word DHEA can describe products with different routes, regulatory status, ingredients, evidence, and prices. An oral supplement, a compounded oral prescription, a compounded DHEA-and-estradiol vulvar cream, and an FDA-approved vaginal insert are not four interchangeable versions of the same treatment.

So when a friend says DHEA changed her life and a clinician says the evidence is weak, they may be talking about different products, different symptoms, or an individual experience versus the average result in a controlled trial.

Let's sort out which one you're actually looking at.

---

Best for / Not for you

DHEA is probably the right conversation if: your main problem is moderate-to-severe pain during sex after menopause caused by vulvar and vaginal changes. That is where the FDA approval for vaginal prasterone lives. Vaginal DHEA also appears in professional guidance as one local option for genitourinary syndrome of menopause, but the exact US label is narrower than “all dryness” or “all urinary symptoms.” Intrarosa prescribing information

DHEA is probably the wrong purchase if: your main problem is low desire without pain, brain fog, hot flashes, weight, energy, mood, or general wellbeing. Systemic DHEA has not shown dependable benefit for those goals, and the international testosterone consensus specifically recommends against it for hypoactive sexual desire disorder in postmenopausal women with normal adrenal function. Global Consensus Position Statement

Do not self-start it from an internet page if: you have bleeding after menopause, a current or past breast cancer, possible pregnancy, rapidly changing facial hair or voice, new pelvic pain, vulvar sores or skin changes, or a tested-sport obligation. Those facts change the starting point.

---

What “DHEA” means, in one table

DHEA is one molecule used in several legally and clinically different product types. The route and finished formulation determine what was actually studied, what FDA reviewed, what the product may be prescribed for, and what a price comparison means.

Product category	What it legally is	Route and published formulation	FDA-approved menopause use?	Public price checked August 31, 2026	What the price does not tell you
OTC oral DHEA supplement	Dietary supplement	Swallowed; label strengths vary	No	No single valid marketwide price	FDA does not approve dietary supplements for safety or effectiveness before marketing, and there is no FDA-approved oral menopause dose. FDA supplement rules
Winona compounded oral DHEA	Prescription compounded drug	Oral capsule once daily; Winona publishes 25 mg as its usual dose and 50 mg as its ceiling	No	From $27 per three-month supply, provider-stated	This is Winona's commercial offer, not an approved DHEA dose and not evidence that the capsule improves the symptoms the provider lists. Winona DHEA page
Midi DHEA/estradiol cream	Prescription compounded drug	External vulva, once daily; DHEA 0.75% plus estradiol 0.01%	No	$90 per 30-day supply (30 mL), provider-stated	It contains estradiol, is not DHEA alone, is not inserted like Intrarosa, and has not been established as equivalent to an FDA-approved product. Midi product page
Intrarosa (prasterone)	FDA-approved prescription drug	6.5 mg vaginal insert once daily at bedtime	Yes — for moderate-to-severe dyspareunia due to menopausal vulvar and vaginal atrophy	Eligible commercially insured patients may pay as little as $35 for 28 inserts; other paths are detailed below	Eligibility, insurance, pharmacy, coupon, and cash status can change the amount sharply. Official commercial savings page

Read that last column before comparing a dollar. This is a price-of-access table, not a dose-equivalence table. A 6.5 mg vaginal insert is not a substitute for 25 mg swallowed. A DHEA-and-estradiol cream is not DHEA alone. These products target different problems by different routes with different evidence.

The line worth remembering: The only DHEA product with an FDA-approved menopause indication in the United States is a prescription vaginal insert — not an oral pill.

---

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

→ Match my situation to the right starting point

---

What women are actually trying to figure out

The real search is not “is DHEA good?” Women are trying to separate an inexpensive oral supplement from a costly prescription insert, understand whether DHEA does something vaginal estrogen does not, and avoid guessing about dose, safety, and long-term use.

“Looking for info on using OTC DHEA tablets … vs expensive Intrarosa.” Source

“I know nothing about how it works, side effects, or long term safety.” Source

“Does DHEA do something that the regular vaginal estrogen cream doesn't do? I'm confused here.” Source

These are reader questions, not evidence. We are showing them because they describe the confusion accurately — not because one person's experience proves that a product works. We do not use anecdotes as proof of safety or benefit.

Notice what all three have in common. They are asking which DHEA, for which symptom, by which route, at what risk and cost.

---

Is DHEA a hormone, a supplement, or a type of HRT?

DHEA is a steroid hormone precursor made mainly by the adrenal glands, but a product containing it may be regulated as a dietary supplement, a compounded prescription drug, or an FDA-approved prescription drug. “DHEA” identifies the molecule; it does not tell you the route, product quality, evidence, or approved use. MedlinePlus DHEA-S guide

DHEA stands for dehydroepiandrosterone. DHEA-S, or DHEAS, is the sulfated form commonly measured in blood. The body can convert DHEA into active androgens and estrogens. Intrarosa's label describes prasterone as an inactive endogenous steroid that is converted into active androgens and/or estrogens; it also says the exact mechanism for its approved use is not fully established. Intrarosa prescribing information

That does not make every DHEA product “HRT” in the same legal or clinical sense:

• A shelf bottle is a dietary supplement.
• A pharmacy-prepared capsule or cream is a compounded drug.
• Intrarosa is an FDA-approved drug.
• “Bioidentical” does not establish dose accuracy, FDA approval, route equivalence, clinical benefit, or safety.

Natural decline is not an automatic replacement indication. DHEA-S levels fall with age, but the Endocrine Society recommends against diagnosing a generalized androgen-deficiency syndrome in healthy women and against routine DHEA use because efficacy and long-term safety evidence are inadequate. Endocrine Society guideline

---

Does DHEA for menopause actually work?

It depends entirely on the symptom and the route. Prescription vaginal prasterone has FDA approval and controlled-trial evidence for postmenopausal painful sex caused by vulvar and vaginal atrophy. Oral DHEA has not shown consistent benefit for libido, quality of life, cognition, weight, metabolic outcomes, or menopause symptoms as a group.

Here is the evidence map. We sorted it by the symptom a woman is trying to solve, not by whichever product a company sells.

Your main symptom or goal	Route studied	Strongest defensible conclusion	Decision
Moderate-to-severe painful sex after menopause caused by vulvar and vaginal atrophy	Vaginal prasterone 6.5 mg	Improved the label's pain score and vaginal tissue measures versus placebo in two 12-week trials; FDA-approved for this use	Evidence-matched conversation
Choosing vaginal prasterone versus vaginal estradiol	Vaginal	A 2026 open-label randomized trial found a mixed result: the severe-dyspareunia subgroup favored DHEA, while estradiol improved pH, maturation index, and clinical atrophy signs more	Outcome-specific decision; no universal winner
Low sexual desire / HSDD	Systemic oral DHEA	Not associated with meaningful improvement in libido or sexual function in postmenopausal women with normal adrenal function; cannot be recommended for HSDD	Wrong purchase for this goal
Sexual function across pooled oral trials	Oral	No statistically significant improvement in a 23-trial review: SMD 0.35, 95% CI −0.02 to 0.73; P=.06	Not established
Quality of life	Mostly oral	Cochrane found no evidence of improvement	Not supported
Menopause symptoms overall	Mostly oral	Cochrane found the effect uncertain	Not a dependable treatment plan
Memory and thinking	Oral	A 2023 systematic review did not support cognitive benefit	Not supported
Weight, BMI, glucose, lipids, bone mineral density	Systemic oral	The 23-trial review found no significant effect on these outcomes	Not a weight, metabolic, or bone treatment
Raising estradiol or testosterone in blood	Oral	A 2025 meta-analysis found both rose on average	Biological effect, not proof of symptom relief

Source: Intrarosa prescribing information, 2026 DHEA-versus-estradiol trial, Global Consensus Position Statement, Elraiyah review, Cochrane review, Sultana cognition review, and 2025 hormone-level meta-analysis.

Two things about that table, said plainly

First: a P value of .06 is not “proven useless.” In the pooled sexual-function analysis, the confidence interval crossed no effect and the result did not meet the usual statistical threshold. The honest conclusion is we cannot say it worked, not that researchers proved every woman receives zero benefit. Elraiyah review

Second: the studies did not avoid commercially relevant doses. A 52-week trial in postmenopausal women with low libido tested 50 mg a day and found no significant improvement in sexual function, wellbeing, or menopause symptoms. Winona currently publishes 25 mg as its usual dose and 50 mg as its maximum. The “the research never tested what women actually take” escape hatch does not hold up here. Panjari trial Winona DHEA page

DHEA can move a hormone number without moving the symptom that made you spend the money.

That is the central distinction on this page.

---

Does DHEA help low libido after menopause?

This is the benefit oral DHEA is marketed hardest for, and it has the clearest recommendation against it. The 2019 Global Consensus Position Statement concludes that systemic DHEA does not meaningfully improve libido or sexual function in postmenopausal women with normal adrenal function and cannot be recommended for HSDD. Global Consensus Position Statement

We have to tell you the thing that costs us the click.

If desire is why you are here, the best evidence says oral DHEA is probably the wrong purchase. Not “guaranteed to fail for every woman.” Not “nothing ever happens.” Not recommended for the condition it is being sold hardest to solve.

The underlying 52-week randomized trial was specific: postmenopausal women with low libido took 50 mg of oral DHEA daily. The trial found no significant improvement over placebo in sexual function, wellbeing, or menopause symptoms; androgenic effects including acne and increased hair growth occurred more often with DHEA. Panjari trial

Now here is why knowing that is worth more than the bottle

Low desire is not one problem. Pain, sleep, mood, relationship context, medications, vaginal tissue changes, arousal, and HSDD can all produce the same search phrase.

If pain is part of why desire dropped, removing that pain can remove one reason desire has fallen. That points toward a local GSM evaluation, not an oral DHEA capsule.

If desire itself is the problem, with no pain, the only evidence-based indication for testosterone in women is postmenopausal HSDD after a formal biopsychosocial assessment. There is no FDA-approved testosterone product formulated for women in the United States, so prescribing is off-label, clinician-directed, and monitored. Testosterone is also a Schedule III controlled substance in the US. Global Consensus Position Statement DEA schedules

Either way, you now know to stop treating “low libido” as a one-word supplement problem.

If low desire is what brought you here, DHEA probably isn't your answer — but something might be. Find My HRT Path asks about your symptoms, history, and state, then shows which care route is worth a consult and when online care is not the right starting point. It takes about 90 seconds, needs no email or account, and keeps your health answers on the page.

→ Match my symptoms to the right route

---

Can DHEA help vaginal dryness and painful sex?

Yes — this is the one place where a DHEA product has both FDA approval and controlled-trial evidence. Intrarosa is a 6.5 mg vaginal prasterone insert used once nightly for moderate-to-severe painful sex caused by menopausal vulvar and vaginal atrophy. Its exact US indication is pain during sex, not every symptom under the GSM umbrella. Intrarosa prescribing information

Genitourinary syndrome of menopause, or GSM, can include dryness, burning, irritation, painful sex, and urinary symptoms. Professional menopause guidance recognizes intravaginal DHEA as one option for sexual pain related to GSM. The Menopause Society sexual-health guidance

If you skim nothing else on this page, read the numbers.

What the FDA trials actually showed

Most pages say “studies show it works.” We pulled the exact figures from the FDA-approved label so you can see the size of the drug-specific effect.

12-week trial	Prasterone mean change in pain score	Placebo mean change	Difference versus placebo	P value
Trial 1	−1.27	−0.87	−0.40	.0132
Trial 2	−1.42	−1.06	−0.35	.0002

Intrarosa prescribing information, Clinical Studies

Read those middle columns again. The placebo group improved too — substantially. The drug-specific difference was 0.40 points in one trial and 0.35 points in the other on the label's severity scale.

That is a real statistically significant effect. It is also modest, and it is not “pain eliminated.”

The vaginal tissue measures moved more clearly: superficial cells increased, parabasal cells fell, and vaginal pH decreased versus placebo. Those findings show a tissue response. They are not the same endpoint as how a woman feels.

The honest limits of those trials

The pivotal placebo-controlled trials do not establish that prasterone:

• Is the universal winner over vaginal estrogen across symptoms and tissue outcomes.
• Treats hot flashes.
• Treats general low desire without vulvovaginal atrophy.
• Improves energy, weight, mood, or cognition.
• Works the same in perimenopausal women.
• Makes an OTC or compounded product equivalent.
• Produces the same result for every woman.

Those two trials ran 12 weeks and enrolled postmenopausal women with mean ages of 58.6 and 59.5 years. They compared prasterone with placebo, not with vaginal estrogen. A separate 2026 head-to-head study is covered below. Intrarosa prescribing information

That narrowness is useful. It tells you exactly who has a strong reason to ask about this route — and who should stop trying to make DHEA fit a different problem.

The route mistake we see constantly

Oral DHEA produces systemic exposure. Postmenopausal dyspareunia from vulvar and vaginal atrophy is a local tissue problem.

A company can sell oral DHEA and use words such as “vaginal tissue” on the product page. That does not turn an oral capsule into the product or route studied for the FDA indication.

If vaginal dryness or pain is the main reason you want DHEA, the capsule is the wrong comparison. Compare local options: prescription vaginal prasterone, FDA-approved vaginal estrogen products, ospemifene where appropriate, moisturizers, lubricants, pelvic-floor care, and an exam when the cause is unclear.

There is no Intrarosa or dispensing-pharmacy affiliate link in this guide. We are telling you about it because it is the DHEA route with an FDA approval behind it.

---

Please don't put an oral DHEA tablet in your vagina

An oral DHEA supplement is not a substitute for an FDA-approved vaginal insert and should not be used that way. Its dose, excipients, dissolution, absorption, microbiological suitability, stability, and vaginal-tissue tolerability were not established by the Intrarosa label or trials.

The Intrarosa studies used a specific 6.5 mg solid-fat vaginal insert with a supplied single-use applicator. They did not study a swallowed tablet placed vaginally. Intrarosa prescribing information

We are including this section because women are openly discussing the workaround for one legitimate reason: the prescription can cost too much.

That reason is legitimate. The workaround is not.

Here is what changes when an oral product is used by a route it was never designed for:

• The dose comparison breaks. A number printed on an oral label does not establish an equivalent vaginal exposure.
• The other ingredients change. Binders, fillers, coatings, capsule materials, and disintegration characteristics were selected for oral use.
• The release changes. The finished product was not tested to dissolve or distribute as a vaginal insert.
• The quality question changes. Legal sale as an oral supplement does not establish suitability, stability, or tissue tolerance for vaginal use.
• Responsibility disappears. No approved label, prescriber, or dispensing pharmacist is taking responsibility for that improvised formulation.

If cost is the barrier, use the documented savings paths below or ask a clinician to compare lower-cost FDA-approved local options. A clinician-directed compounded vaginal product is also a different category from DIY use: it has a defined prescription, dose, route, and preparation supplied by a compounding pharmacy or outsourcing facility. It still is not FDA-approved and is not established as equivalent to Intrarosa. FDA compounding guidance

Please do not do this one alone.

---

Is vaginal DHEA the same as vaginal estrogen?

No. Vaginal estrogen delivers an estrogen directly, while prasterone delivers a steroid precursor that vaginal cells convert into androgens and estrogens. They are not interchangeable. A 2026 open-label randomized trial found a mixed result: DHEA performed better in the severe-dyspareunia subgroup, while estradiol improved pH, maturation index, and clinical atrophy signs more. 2026 DHEA-versus-estradiol trial

Option	What it delivers	FDA-labeled role	Hormonal?
Prasterone (Intrarosa)	Steroid precursor converted into androgens and estrogens	Moderate-to-severe dyspareunia due to menopausal vulvar and vaginal atrophy	Yes
Low-dose vaginal estrogen	Estrogen	Product-specific indications for menopausal vulvar/vaginal symptoms	Yes
Ospemifene	Oral selective estrogen receptor modulator	Product-specific indication for moderate-to-severe dyspareunia and/or vaginal dryness	Not estrogen, but acts at estrogen receptors
Moisturizers and lubricants	Non-drug products	Symptom support; not drug equivalents	No

What the first direct DHEA-versus-estradiol trial found

The 2026 trial randomized 172 naturally postmenopausal women with moderate or severe dyspareunia to vaginal DHEA 6.5 mg or vaginal estradiol 10 micrograms. It was open-label. Both groups used treatment daily for four weeks and then twice weekly through week 12. 2026 DHEA-versus-estradiol trial

Week-12 outcome	Vaginal DHEA	Vaginal estradiol	What the comparison means
At least a 1-point improvement in dyspareunia	92%	82%	Overall odds ratio 2.87, 95% CI 1.00–8.25; P=.051, so the overall difference narrowly missed the conventional statistical threshold
Improvement among women with severe dyspareunia at baseline	Higher odds with DHEA	Lower odds than DHEA	Odds ratio 3.4, 95% CI 1.07–10.5, favoring DHEA in this subgroup
Vaginal pH, maturation index, and total clinical signs of atrophy	Improved	Improved more	Estradiol performed better on these tissue and clinical-sign measures

That is not a one-product-wins-everything result. The pain outcome and the tissue-sign outcomes pointed in different directions. The trial was open-label, lasted 12 weeks, and used twice-weekly DHEA after week four rather than the US Intrarosa label's nightly maintenance schedule. Do not use it to rewrite the approved dose.

The useful conclusion is narrower: the symptom and outcome you care about can change which local option deserves the first conversation.

The wording correction that matters

You will see prasterone described as non-estrogen. That describes the administered product.

You will also see it described as nonhormonal or as having no systemic exposure. Those descriptions are not accurate.

The FDA label states that prasterone is converted into active androgens and/or estrogens. After seven daily doses, testosterone and estradiol exposure were slightly higher than with placebo; estradiol peak concentration was 5.04 pg/mL with Intrarosa versus 3.33 pg/mL with placebo. Intrarosa prescribing information

Local means the treatment is delivered where the problem is. It does not mean zero reaches the bloodstream.

The 2026 label change — and what it does not prove

In November 2025, FDA initiated removal of certain boxed-warning statements from menopausal hormone therapy labels. In February 2026, the agency approved the first six updated labels, including Estring, a topical vaginal estrogen product. Intrarosa was not on that list. The FDA action addressed estrogen and progestogen menopausal hormone therapy products; it was not a head-to-head safety review of Estring versus Intrarosa. FDA labeling action FDA updated-product list

The paperwork moved for one drug class and not the other. That is a real label difference. It is not evidence that one product is safer than the other.

But it closes one shortcut: choosing DHEA only because “it isn't estrogen, so it must be safer for my breast history” is not supported by the current Intrarosa label. The label says estrogen is a prasterone metabolite and warns about current or past breast cancer. Intrarosa prescribing information

That is a specialist conversation, not a marketing slogan.

---

Is DHEA safe if you've had breast cancer?

This is the one question here that a website cannot clear for you. The Intrarosa label warns about current or past breast cancer, states that estrogen is a prasterone metabolite, and says the product was not studied in women with a breast cancer history. ACOG describes a possible clinician-directed vaginal DHEA path when vaginal estrogen is not an option. Intrarosa prescribing information ACOG clinical consensus

Two authoritative documents are doing different jobs:

Source	What it says	What it means
Intrarosa FDA-approved prescribing information	Estrogen is a prasterone metabolite; Intrarosa has not been studied in women with a history of breast cancer	The label does not clear this population
ACOG Clinical Consensus for people with estrogen-dependent breast cancer history	Nonhormonal treatments are first-line; if vaginal estrogen is not an option, vaginal DHEA or testosterone may help dyspareunia and vaginal tissue health	A specialist may consider it after weighing the cancer history, symptom severity, prior treatments, and alternatives

They are not permission for self-treatment.

What it means for you: a breast cancer history does not make your symptoms untreatable. It ends the version of this decision made from a product page or a generic telehealth intake alone.

Bring the current label and the ACOG consensus to the clinician managing your cancer history. Ask how your cancer type, receptor status, current endocrine therapy, recurrence risk, symptom severity, and failed nonhormonal options change the decision.

There is deliberately no product link or conversion button in this section.

---

Does DHEA raise estrogen and testosterone — and does that mean it's working?

Yes to the first part. Not necessarily to the second. A 2025 meta-analysis of 21 randomized trials found oral DHEA raised total testosterone by an average of 24.31 ng/dL and estradiol by an average of 7.86 pg/mL in postmenopausal women. Those are laboratory outcomes, not proof that menopause symptoms improved. 2025 meta-analysis

This is the single most important idea on this page:

A hormone level moving is not a symptom improving.

Pooled laboratory outcome	Average change with oral DHEA
Total testosterone	+24.31 ng/dL
Estradiol	+7.86 pg/mL
Testosterone in studies using at least 50 mg/day	+29.65 ng/dL
Estradiol in participants aged 60 or older	+8.92 pg/mL

2025 meta-analysis

So DHEA does something measurable. Then look back at the symptom evidence: no dependable improvement in libido, wellbeing, cognition, weight, BMI, glucose, lipids, or quality of life across the stronger systemic evidence.

That gap is the story. It is also why “we will optimize your levels” sounds persuasive while leaving the outcome that matters unanswered.

The number is easy to move. The symptom is the hard part. The symptom is the part you live with.

Two groups should say this out loud at the first appointment:

• If you have a uterus: “How does this proposed product fit with my current estrogen and progesterone plan, and what bleeding should trigger evaluation?”
• If you have a hormone-sensitive cancer history: “Which evidence applies to my exact cancer history and current treatment?”

DHEA is not a testosterone-only lever. It can increase estrogen exposure too.

---

My DHEA-S came back low. Does that mean I need DHEA?

No — not by itself. DHEA-S peaks early in life and declines with age, and reference ranges differ by age and sex. Mayo Clinic Laboratories says levels fall to roughly 20% of peak over 40 to 60 years, the clinical meaning of that decline is unknown, and replacement trials in older adults have not produced convincing benefits. Mayo Clinic Laboratories DHEA-S guide

If a clinic showed you a low number and offered you a product in the same conversation, this is the moment to slow down, not speed up.

A DHEA-S result needs three pieces of context:

1. 1. The age-specific range from the laboratory that ran it.
2. 2. The clinical reason the test was ordered.
3. 3. The symptom or adrenal-androgen question the result is supposed to clarify.

A number below a young-adult range is not automatically abnormal for an older woman. A result outside an age-specific range can matter, but it still does not establish that DHEA caused a symptom or that supplementation will fix it.

What DHEA-S testing is actually used for

MedlinePlus describes DHEA-S testing as part of evaluating adrenal function and androgen-related conditions. Depending on the clinical situation, it may help investigate:

• Signs of androgen excess, such as unusual facial or body hair, acne, or voice change.
• Possible adrenal tumors or other adrenal disorders.
• Certain ovarian or testicular disorders.
• Early puberty or related endocrine questions.
• Treatment monitoring in selected circumstances.

MedlinePlus DHEA-S guide

Testing is not a universal entry ticket to menopause treatment. When DHEA is already being used, a clinician may use symptoms and laboratory data as safety information, especially to avoid androgen excess. Mayo Clinic Laboratories notes that overtreatment effects are particularly likely in postmenopausal women when DHEA-S approaches or exceeds the upper reference range. Mayo Clinic Laboratories DHEA-S guide

Five questions to ask about your result

1. 1. Why was this test ordered — what clinical question was it meant to answer?
2. 2. Is the value being compared with an age- and sex-appropriate range from this laboratory?
3. 3. Which specific symptom is expected to improve if we treat it?
4. 4. How will we measure whether that symptom improved?
5. 5. Would the treatment plan be different if this test had never been ordered?

If nobody can answer question three with a specific symptom, you do not have a treatment plan. You have a number.

---

Is DHEA the same as testosterone?

No. DHEA is a precursor the body can convert into both testosterone and estrogen; taking it is not the same as taking testosterone. DHEA is not federally scheduled, while testosterone is a Schedule III controlled substance in the United States and requires a prescription plus controlled-substance compliance. DEA schedules

That regulatory difference is real. It can make the operational paths different:

• Testosterone prescribing and dispensing must comply with federal and state controlled-substance rules.
• DHEA supplements are sold over the counter.
• Compounded prescription DHEA is still a prescription drug, but DHEA itself is not federally scheduled.
• No testosterone product is FDA-approved specifically for women in the United States.

What the evidence does not let us do is infer that any specific provider chose DHEA mainly to avoid controlled-substance friction unless the provider says so. Business motive is not a medical fact.

The clinical decision is separate:

• Systemic DHEA cannot be recommended for HSDD in postmenopausal women with normal adrenal function.
• Testosterone's evidence-based indication in women is postmenopausal HSDD after formal biopsychosocial assessment.
• Testosterone treatment for women in the US is off-label and requires careful dose and monitoring decisions.
• Supraphysiologic dosing, pellets, and unmonitored use are not the evidence-based route.

Global Consensus Position Statement

If testosterone is what you are actually trying to evaluate, start with the low-libido guide, not an oral DHEA checkout page.

---

How much DHEA do women take, and how long does it take to work?

The only FDA-labeled menopause dose is Intrarosa 6.5 mg vaginally once daily at bedtime. There is no FDA-approved oral DHEA dose for menopause. Research and provider pages commonly use or publish 25 mg and 50 mg oral doses, but a study dose or commercial default is not a self-treatment instruction. Intrarosa prescribing information

We are not going to give you an oral dose to take. That is a real answer, not a dodge.

The approved vaginal dose

The US label says:

• One 6.5 mg vaginal insert.
• Once daily.
• At bedtime.
• Using the provided single-use applicator.

Intrarosa prescribing information

Why there is no general oral dose here

• Oral DHEA has no FDA-approved menopause indication.
• There is no FDA-approved oral menopause dose.
• Trials used defined populations, outcomes, screening, and monitoring.
• A higher dose can create a larger hormone-level change without a proven symptom benefit.
• Product category, medications, cancer history, androgenic symptoms, and pregnancy possibility change the risk.

Winona publishes 25 mg as an effective dose for most menopausal women and 50 mg as its maximum. That is a provider-stated prescribing policy, not an independent guideline and not proof of efficacy for the long symptom list on its product page. Winona DHEA page

How long does vaginal prasterone take?

The pivotal trials measured their primary efficacy endpoints at 12 weeks. The manufacturer also uses 12 weeks in its public results language. That is the study endpoint, not a guarantee that every woman feels a result on the same date. Intrarosa prescribing information

Before starting any treatment, agree on:

1. 1. The one symptom being tracked.
2. 2. How change will be measured.
3. 3. The reassessment date.
4. 4. Which effects trigger an earlier call.
5. 5. What happens if the symptom does not move.

Do not turn “no benefit” into an automatic reason to double a dose.

---

What does DHEA cost in 2026?

There is no honest single price for “DHEA” because the products are not equivalent. As checked August 31, 2026, Winona published compounded oral DHEA from $27 per three-month supply, Midi published a DHEA/estradiol vulvar cream at $90 per 30 days, and Intrarosa ranged from a $35 commercial-insurance program to more than $300 cash.

Current published price and access table

Product or access path	Amount observed August 31, 2026	Normalized daily amount	Eligibility or condition	Source type
Winona compounded oral DHEA	From $27 per three-month supply	Not normalized here; verify capsule count, dose, and refill schedule at checkout	Prescription after evaluation; Winona does not bill insurance directly	Provider-stated source
Midi compounded DHEA/estradiol external vulvar cream	$90 per 30-day supply (30 mL)	$3.00/day if used as the published 30-day supply	A Midi visit is required; Midi says Custom Rx products are cash-pay and not covered by insurance	Provider-stated sources [midi-store]
Intrarosa commercial-insurance program	As little as $35 for 28 inserts	$1.25/day	Eligible commercially insured patients; terms and limits apply	Manufacturer program source
Intrarosa Medicare program	Most eligible patients may pay as little as $85	$3.04/day for 28 inserts	Medicare Part D or Medicare Advantage prescription coverage; participant must meet the program's opt-out and no-reimbursement conditions	Manufacturer program source
Intrarosa GoodRx coupon	$233.16 for 28 inserts	$8.33/day	Dynamic coupon and pharmacy price	Third-party observed price source
Intrarosa Drugs.com cash estimate	$321.88 for 28 inserts	$11.50/day	Cash-paying estimate; pharmacy dependent	Third-party observed price source
Intrarosa GoodRx displayed retail	$380.63 for 28 inserts	$13.59/day	Dynamic retail benchmark, not a guaranteed checkout price	Third-party observed price source

Medication price is not the total cost of entry

Route	What the published medication price includes	Care-cost and continuity context checked August 31, 2026
Winona compounded oral DHEA	From $27 per three-month supply	Winona says the online medical evaluation, standard shipping, unlimited physician messaging, and dose adjustments are included. It runs as an auto-refill subscription that can be canceled at any time. Winona DHEA page
Midi compounded DHEA/estradiol cream	$90 per 30-day supply	A Midi visit is required. Midi lists self-pay visits at $250 initially and $150 for follow-up, while insured visit cost depends on the plan. Midi says Custom Rx medications are cash-pay and not covered by insurance; it publishes no membership fee. Midi pricing Midi Custom Rx FAQ
Intrarosa	The commercial, Medicare, coupon, or cash amount for 28 inserts	A prescription is required. The clinician-visit cost depends on where care is obtained and is separate from the medication savings amounts shown here.

Do not compare the first row with the Intrarosa rows as if the dose or treatment were interchangeable. The useful comparison is:

• Oral versus oral, for the same labeled strength and quantity.
• External compounded combination cream versus its own alternatives.
• FDA-approved local therapy versus other local prescription options.

The insurance sentence that needed fixing

“Covered,” “not covered,” and “HSA/FSA eligible” are not universal product properties.

• The Intrarosa manufacturer says most insurance plans cover it, but each reader still has to verify formulary status, prior authorization, step therapy, deductible, and pharmacy. Official Intrarosa FAQ
• The commercial and Medicare savings routes have different eligibility rules and must not be collapsed into one “starting at” number.
• A provider accepting an HSA or FSA card does not guarantee that every purchase is a qualified medical expense.
• IRS guidance says a nutritional supplement can be paid or reimbursed through an HSA/FSA only when a medical practitioner recommends it to treat a specific medical condition diagnosed by a physician; otherwise it is not a medical expense. IRS guidance

Questions that prevent the surprise bill

1. 1. Is the price for 28 inserts, 30 days, three months, or a different refill interval?
2. 2. Is it the first fill only or every fill?
3. 3. Does it require commercial insurance?
4. 4. Does a Medicare savings path require opting out of plan reimbursement?
5. 5. Does the amount count toward a deductible or TrOOP?
6. 6. Is prior authorization or step therapy required?
7. 7. Which pharmacies participate?
8. 8. What is the price after a coupon or program ends?
9. 9. Is the product FDA-approved, compounded, or a supplement?
10. 10. Does the quoted product actually match the symptom?

---

Where can you get DHEA prescribed online?

Winona and Midi currently publish online DHEA products, but they do not sell the same thing. The safest comparison is not “who sells DHEA?” It is “which route matches my symptom, what exactly is in the product, and is the product FDA-approved or compounded?”

Care path	Product published	Current provider-stated facts	FDA status	The HRT Index's editorial fit conclusion
Winona	Compounded oral DHEA capsule	From $27 per three-month supply; once daily; 25 mg published as usual dose and 50 mg as maximum; evaluation, standard shipping, and unlimited messaging included; auto-refill subscription can be canceled at any time	Not FDA-approved	A defined, clinician-prescribed oral trial may appeal to an existing Winona patient who understands the weak systemic evidence. It is not the evidence-matched route for postmenopausal painful sex, and it is not recommended for HSDD.
Midi Health	Compounded DHEA 0.75% plus estradiol 0.01% cream	$90 per 30-day supply; applied to the external vulva once daily; visit required; Custom Rx medication is cash-pay and not covered by insurance	Not FDA-approved	This is a combination external-vulvar product, not DHEA alone and not an Intrarosa substitute. Its cancer-survivor and combination-use claims on the product page require individual clinical review; they are provider statements, not independent clearance.
A licensed prescriber who can prescribe Intrarosa	FDA-approved prasterone 6.5 mg vaginal insert	One insert nightly; insurance and savings eligibility vary	FDA-approved	This is the evidence-matched DHEA route for the narrow labeled postmenopausal dyspareunia population. It does not require a particular telehealth brand.

Winona product page Winona state-availability page Midi product page Midi Custom Rx FAQ Midi pricing Intrarosa prescribing information

Winona publishes a state-specific service list rather than a universal all-state promise. Midi advertises general virtual-care availability in all 50 states, but the Custom Rx product still requires an individual clinician decision and pharmacy fulfillment. Check current product availability before paying. Winona state-availability page Midi availability

The HRT Index has affiliate relationships with Winona and Midi Health. There is no direct affiliate provider link in this guide. Both rows remain because they represent two current product categories a searcher is likely to encounter. Full affiliate disclosure

Three questions that prevent the most common mistakes

1. 1. Which product is this? Oral capsule, external vulvar combination cream, compounded vaginal preparation, or FDA-approved vaginal insert?
2. 2. Is it being added to something or used instead of something? A DHEA-and-estradiol cream alongside vaginal estrogen is a different plan from oral DHEA alone.
3. 3. Is the finished medication FDA-approved or compounded? Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness, or quality before marketing. They are not FDA-approved generics. FDA compounding guidance

The damaging admission about the oral prescription

A Winona prescription does not make oral DHEA FDA-approved or prove that it improves libido, cognition, weight, metabolism, energy, or vaginal pain. Its published $27 three-month price buys a care bundle, not stronger clinical evidence.

The defensible value case is narrower: a named product, a published provider dose ceiling, clinician review, a medication record, and ongoing access to the prescriber. Whether those features justify the price depends on the symptom and whether the clinician can explain what result would make the trial worth continuing.

→ Find the care route that matches my symptom before choosing a provider

---

Is DHEA safe for women after menopause?

There is no route-independent yes or no. Oral DHEA is most consistently associated with androgenic effects such as acne and unwanted hair growth. Intrarosa's label lists undiagnosed abnormal genital bleeding as a contraindication, warns about current or past breast cancer, and identifies vaginal discharge and abnormal Pap findings as common adverse reactions.

What the Intrarosa label actually reports

Trial setting	Finding
Four 12-week placebo-controlled trials	Vaginal discharge: 5.71% with Intrarosa versus 3.66% with placebo
One 52-week open-label trial	Vaginal discharge: 14.2%; abnormal Pap smear: 2.1%

The 11 abnormal Pap results in the 52-week study included one low-grade squamous intraepithelial lesion and 10 results with atypical cells of undetermined significance. The 52-week study had no placebo comparison, so those numbers cannot be read as a controlled excess versus no treatment. Intrarosa prescribing information

Oral DHEA effects and limits

Cochrane found some evidence of androgenic adverse effects, particularly acne and unwanted hair growth. Its pooled estimate for androgenic effects favored placebo, while the long-term safety evidence remained limited. Cochrane review

Other practical concerns include:

• Oily skin.
• Scalp or body-hair changes.
• Increasing estradiol as well as testosterone.
• Product-specific quality and dose differences.
• Treating a lab value without a symptom benefit plan.
• Adding it to another hormone regimen without a prescriber reviewing the exact products and doses.

Do not convert “endogenous,” “natural,” or “bioidentical” into “risk-free.”

The tested-athlete disqualifier

DHEA is prohibited at all times under WADA rules, regardless of route, unless the athlete has an approved Therapeutic Use Exemption. USADA explicitly includes Intrarosa and says testosterone or DHEA in any amount and by any route is prohibited without an approved TUE. USADA DHEA guidance

That applies to:

• OTC supplements.
• Compounded prescriptions.
• Topical or vulvar preparations.
• Intrarosa.
• Any other product containing DHEA.

Stop self-selecting online and contact a clinician if

• You have bleeding after menopause that has not been evaluated.
• You have new or severe pelvic pain.
• You have vulvar skin changes, sores, or recurrent infections.
• You develop rapidly changing facial/body hair, scalp hair loss, or voice change.
• You have a current or past hormone-sensitive cancer.
• Pregnancy is possible.
• You compete under anti-doping rules and do not have an approved TUE.

None of those are internet purchase decisions.

If DHEA is off the table because of your history, sport, or symptom mismatch, you still have options.

→ See which routes remain for my situation

---

Does DHEA work differently in perimenopause versus after menopause?

The FDA-approved vaginal indication is specifically for postmenopausal women. Both pivotal efficacy trials and the 52-week safety study enrolled postmenopausal participants; evidence for oral DHEA in perimenopause is limited, and a woman who could become pregnant is making a different decision from a woman years past her final period. Intrarosa prescribing information

The label trial populations were:

• Trial 1: 255 postmenopausal women, ages 40 to 75, mean age 58.6.
• Trial 2: 558 postmenopausal women, ages 40 to 80, mean age 59.5.
• 52-week safety study: 521 postmenopausal women, mean age 57.9.

Every participant in those label studies was postmenopausal.

So if you are still having irregular periods and considering vaginal prasterone, you are outside the FDA-labeled population and the population that established approval. That does not let an article declare the product right or wrong for you. It means the decision belongs to a clinician who knows your symptoms, pregnancy possibility, history, and alternatives.

Two things change in perimenopause:

• Pregnancy may still be possible. Intrarosa is indicated only after menopause and has no pregnancy-use data.
• Symptoms and endogenous hormones fluctuate. Without a defined symptom and reassessment plan, it becomes hard to tell treatment response from the natural movement of symptoms.

Surgical, treatment-induced, or early menopause also changes the evaluation. Start with the clinician or specialist who understands why menopause occurred rather than treating age alone as the deciding variable.

---

What should you use instead if DHEA isn't your answer?

The right alternative depends on the symptom, not on finding a way to make DHEA fit. Most women who arrive at this page are describing a problem that belongs to a different treatment category, a different route, or an in-person evaluation.

If your main problem is…	The route worth asking about	Where to go next
Painful sex, vaginal dryness, burning, or related urinary symptoms	A GSM evaluation and local options, including FDA-approved vaginal estrogen or prasterone where appropriate	Vaginal estrogen guide
Symptoms persist while using systemic HRT	Local-versus-systemic add-on evaluation	Vaginal estrogen with systemic HRT
Low desire without pain	Full biopsychosocial sexual-health evaluation; testosterone only for an appropriate diagnosed HSDD pathway	Low libido guide
Hot flashes or night sweats	Systemic HRT assessment or evidence-based nonhormonal treatment	HRT benefits and risks · Nonhormonal options
Brain fog, mood, sleep, or fatigue	Identify the driver: sleep disruption, vasomotor symptoms, mood, medications, thyroid, anemia, or another medical cause	Mood guide · Sleep guide
Weight or body composition	A separate weight and metabolic-health conversation; DHEA is not a menopause weight treatment	Find My HRT Path
“My lab said low DHEA-S”	Clarify why the test was ordered before treating it	Return to the DHEA-S section
Bleeding after menopause, new pelvic pain, or vulvar changes	Prompt clinical evaluation; online product selection is not the first step	Contact a clinician

Before you start anything, write down two things:

1. 1. The exact symptom you are tracking.
2. 2. The date and measure your clinician will use to decide whether the treatment earned another refill.

→ Find the route that matches my situation

---

What should you ask before you pay for DHEA?

A useful consult should identify the exact symptom, product, route, FDA status, evidence, success measure, reassessment date, and total cost before treatment starts. If the product is compounded, ask why an approved product does not meet the need and identify the exact finished formulation and dispensing pharmacy.

Print this. Take it in. A written portal answer is easier to verify than something remembered from a fast intake.

The questions follow the five pillars in The HRT Index Verification Standard.

Clinical legitimacy

1. 1. Is this an FDA-approved product, an OTC supplement, or a compounded prescription?
2. 2. If it is compounded, which pharmacy prepares the finished medication?
3. 3. Why does an FDA-approved product not meet my clinical need?
4. 4. What is the FDA-approved indication for this product, if it has one?

Care quality

1. 1. What exact symptom are we treating?
2. 2. What evidence connects this route to that symptom in someone with my menopause stage and history?
3. 3. Which benefit will we measure, and on what date will we reassess?
4. 4. Which effect should make me contact you before that date?
5. 5. Who answers questions between visits?

Medication fit

1. 1. What is the route, exact dose, full ingredient list, and dose ceiling?
2. 2. Is this being added to my current treatment or replacing something?
3. 3. How does this interact with my estrogen, progesterone, testosterone, antidepressant, cancer therapy, or other medication?
4. 4. If I have a uterus, how does this fit with my current endometrial-protection plan, and what bleeding requires evaluation?
5. 5. Do I actually need a DHEA-S test, and what clinical question would it answer?
6. 6. If this is compounded, what are the concentration, amount per dose, base or vehicle, storage instructions, and beyond-use date?

Price transparency

1. 1. What will I pay for the evaluation, first fill, refill, and month 12?
2. 2. What quantity and refill interval does that price buy?
3. 3. Is the public price an introductory amount, coupon amount, or ongoing amount?
4. 4. Does insurance require prior authorization or step therapy?
5. 5. Does using a manufacturer or Medicare program affect reimbursement, deductible credit, or TrOOP?
6. 6. Does accepting an HSA/FSA card mean the expense qualifies under my plan, or do I need documentation?

Access

1. 1. Are you licensed to treat me in my state?
2. 2. Where is the prescription filled and shipped from?
3. 3. Can I use a local pharmacy if I stop using this service?
4. 4. What are the cancellation, refill, and refund terms?
5. 5. What happens if the product does not help, and what will the next visit cost?
6. 6. Which symptoms or history require an in-person clinician instead?

---

What we actually verified

This page is editorial research by The HRT Index Editorial Team. It is not medical advice and it is not reviewed by a clinician. Here is exactly what we checked, when, and what we did not claim.

What we read directly

• The current DailyMed record and FDA-approved prescribing information for Intrarosa: indication, 6.5 mg bedtime dose, contraindication, breast-cancer warning, pharmacokinetics, pivotal trial results, adverse-reaction rates, and trial demographics.
• FDA's 2016 Intrarosa approval record.
• FDA's current rules and consumer guidance for dietary supplements and compounded drugs.
• FDA's November 2025 and February 2026 menopausal hormone therapy labeling actions and current list of updated products.
• The 2019 Global Consensus Position Statement, the Endocrine Society guideline, Cochrane review, Elraiyah review, Panjari trial, 2023 cognition review, 2025 hormone-level meta-analysis, and the 2026 randomized comparison of vaginal DHEA with vaginal estradiol.
• ACOG's consensus on genitourinary symptoms in people with an estrogen-dependent breast cancer history.
• Mayo Clinic Laboratories and MedlinePlus guidance on DHEA-S testing and age-related decline.
• USADA's DHEA guidance and DEA's current controlled-substance schedule information.
• IRS guidance on nutritional supplements and HSA/FSA reimbursement.
• Public Winona, Midi, Intrarosa, GoodRx, and Drugs.com pages on August 31, 2026, including medication prices, visit-cost context, insurance or cash-pay language, state-availability language, support, refill, and cancellation terms that were publicly stated.

What the date means

The DailyMed page was checked in August 2026, but the prescribing information displayed there is revised February 2018 and the DailyMed record shows an update date of November 11, 2020. We do not call that an “August 2026 label update.” We call it the current public label we verified in August 2026. Intrarosa prescribing information

Provider prices, manufacturer programs, and third-party pharmacy prices are rechecked monthly. FDA labels, regulatory status, and major guidance are checked quarterly or sooner after a material update. The “Last verified” date changes only after the underlying sources are rechecked.

What we did not do

• We did not take DHEA.
• We did not enroll in a provider program.
• We did not test a supplement in a laboratory.
• We did not call every insurer or pharmacy.
• We did not verify what any individual reader will pay.
• We did not treat a provider's benefit claim as independent evidence.
• We did not infer why a provider chose DHEA unless the provider published that reason.
• We did not use a customer story as proof that a treatment works.

Why there are no treatment-success testimonials here

We looked for an attributable patient account that could be used without turning one person's outcome into efficacy evidence. The Intrarosa website's prominent “Claire G.” story is explicitly labeled an actor portrayal, so it is not presented here as a verified customer testimonial. Official Intrarosa website

The forum quotes near the top are used only to show real decision friction. They are not medical evidence.

---

Frequently asked questions about DHEA for menopause

These short answers keep oral supplements, compounded prescriptions, and FDA-approved vaginal prasterone in their correct categories. The route and target symptom are included because a one-word answer about “DHEA” would be misleading.

Is DHEA good for menopause?

Not as a general all-purpose supplement. The clearest supported use is prescription vaginal prasterone for moderate-to-severe painful sex caused by menopausal vulvar and vaginal atrophy. Oral DHEA is not FDA-approved for any menopause symptom and has not shown consistent benefit for hot flashes, energy, mood, cognition, weight, or overall wellbeing.

Is DHEA an estrogen or testosterone?

Neither. DHEA is a steroid precursor the body can convert into both estrogens and androgens. That is why “not estrogen” does not mean “nonhormonal.”

Is Intrarosa the same as the DHEA in the supplement aisle?

No. Intrarosa contains prasterone, another name for DHEA, but it is a specific FDA-approved 6.5 mg vaginal insert in a solid-fat base with its own applicator. It is not interchangeable with an oral supplement.

Is oral DHEA FDA-approved for menopause?

No. FDA does not approve dietary supplements for safety and effectiveness before marketing, and no oral DHEA product has an FDA-approved menopause indication.

How much DHEA should a menopausal woman take?

The only FDA-labeled menopause dose is Intrarosa 6.5 mg vaginally once daily at bedtime. There is no FDA-approved oral menopause dose. A research dose or provider default is not a universal self-treatment instruction.

Does DHEA help hot flashes?

Not reliably. Oral evidence does not establish DHEA as a dependable vasomotor treatment, and Intrarosa is a local vaginal prescription for dyspareunia — not a hot-flash treatment.

Does DHEA help low libido?

Systemic DHEA cannot be recommended for HSDD in postmenopausal women with normal adrenal function. If pain is suppressing desire, treating the pain is a different decision from treating low desire itself.

Can DHEA help vaginal dryness?

Vaginal prasterone improved vaginal cell and pH measures in its pivotal trials, and professional guidance includes it among GSM options. Its exact US FDA indication is moderate-to-severe dyspareunia, not a blanket vaginal-dryness or urinary-symptom indication.

Is vaginal DHEA the same as vaginal estrogen?

No. Prasterone is a precursor converted into androgens and estrogens; vaginal estrogen delivers estrogen directly. A 2026 randomized open-label trial found a mixed comparison — DHEA favored the severe-dyspareunia subgroup, while estradiol improved pH, maturation index, and clinical atrophy signs more — so they are not automatically interchangeable.

Does vaginal DHEA stay completely local?

No. It is delivered locally, but the label reports slightly higher testosterone and estradiol exposure than placebo. “Local” should not be translated into “zero systemic exposure.”

Can I put an oral DHEA tablet in my vagina?

Do not use an oral supplement as a vaginal insert. The finished oral product's dose, other ingredients, release, absorption, stability, and tissue tolerance were not established for that route.

How long does DHEA take to work?

The pivotal Intrarosa trials assessed the main efficacy outcomes at 12 weeks. That is a study endpoint, not a guaranteed personal timeline. Oral DHEA has no established general menopause-response timeline because it has no approved menopause use and symptom benefits are inconsistent.

Can DHEA cause acne or unwanted hair growth?

Yes. Acne and hirsutism are the most consistently reported systemic androgenic effects in the evidence reviews, and the 50 mg low-libido trial reported more acne and hair growth with DHEA.

Can DHEA help with weight or belly fat?

It is not an evidence-based menopause weight treatment. The 23-trial systemic review found no significant effect on weight or BMI.

Should I take DHEA because my DHEA-S is low?

Not on that fact alone. DHEA-S declines with age, ranges are age-specific, and the clinical meaning of the age-related decline is uncertain. Ask why the test was ordered and which symptom or adrenal question it is meant to answer.

Do I need a DHEA-S test before taking DHEA?

There is no universal routine-test rule for treating menopause symptoms with DHEA. Testing should answer a defined clinical question or support safety monitoring, not manufacture an “androgen deficiency” diagnosis from one number.

Is DHEA safe if I have had breast cancer?

There is no universal website answer. The Intrarosa label warns about current or past breast cancer and says the product was not studied in that population. ACOG describes a possible clinician-directed vaginal DHEA path when vaginal estrogen is not an option. Take the decision to the clinician managing your cancer history.

Is DHEA banned in sport?

Yes. DHEA is prohibited at all times under WADA rules, regardless of route, unless the athlete has an approved TUE. That includes Intrarosa.

Do I need a prescription for DHEA?

OTC oral DHEA supplements do not require a prescription in the United States. Compounded DHEA products and Intrarosa do require a prescription.

Is DHEA a controlled substance?

DHEA is not federally scheduled. Testosterone is a Schedule III controlled substance in the United States. They are not legally or clinically interchangeable.

Can I take DHEA with HRT, vaginal estrogen, testosterone, or an antidepressant?

That is a prescriber decision, not a stacking decision to make alone. Oral DHEA can raise estradiol and testosterone, and vaginal prasterone produces active hormone metabolites. Bring the exact products, doses, and full medication list to the clinician choosing the regimen.

Do I need progesterone with DHEA?

There is no route-independent rule. Intrarosa is not prescribed as systemic estrogen, oral DHEA is not an approved menopause therapy, and compounded combination products vary. Ask how the exact product fits with your uterus status, current estrogen/progesterone plan, bleeding history, and monitoring.

Does insurance cover Intrarosa?

Some insurance and Medicare plans cover it, but formulary status, prior authorization, step therapy, deductible, and pharmacy rules vary. The official commercial and Medicare savings programs have separate eligibility terms.

Is compounded DHEA equivalent to Intrarosa?

No. A compounded drug is not FDA-approved, is not an FDA-approved generic, and has not automatically established the same dose delivery, safety, effectiveness, quality, or therapeutic equivalence as Intrarosa.

---

The decision in one sentence

Use DHEA only when the exact product and route match the exact symptom: prescription vaginal prasterone is evidence-matched to postmenopausal painful sex caused by menopausal vaginal changes; oral DHEA is not a proven all-purpose menopause, libido, cognition, energy, or weight treatment.

Still not sure which HRT program is right for you? Take our free matching quiz. It takes about 90 seconds, needs no email or account, keeps your health answers on the page, and flags when online care is not the right starting point.

→ Take the free Find My HRT Path quiz

---

Sources

Primary regulatory and prescribing sources

1. 1. Intrarosa (prasterone) US prescribing information. DailyMed. Current public record checked August 31, 2026; prescribing information revised February 2018; record updated November 11, 2020.
2. 2. Intrarosa FDA approval letter. US Food and Drug Administration. November 16, 2016.
3. 3. Questions and Answers on Dietary Supplements. US Food and Drug Administration.
4. 4. Compounding and the FDA: Questions and Answers. US Food and Drug Administration.
5. 5. FDA approves labeling changes for menopausal hormone therapy products. US Food and Drug Administration. February 12, 2026.
6. 6. Menopausal hormone therapies with updated prescribing information. US Food and Drug Administration.
7. 7. Controlled Substance Schedules. US Drug Enforcement Administration.
8. 8. IRS frequently asked questions about nutrition, wellness, and medical expenses. Internal Revenue Service.

Guidelines and evidence reviews

1. 1. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Journal of Clinical Endocrinology & Metabolism. 2019.
2. 2. Androgen Therapy in Women: A Reappraisal. Endocrine Society Clinical Practice Guideline. 2014.
3. 3. Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-dependent Breast Cancer. American College of Obstetricians and Gynecologists. 2021; current public guidance checked August 2026.
4. 4. Sexual Health. The Menopause Society patient guidance.
5. 5. Dehydroepiandrosterone for women in the peri- or postmenopausal phase. Cochrane Review.
6. 6. The Benefits and Harms of Systemic Dehydroepiandrosterone in Postmenopausal Women With Normal Adrenal Function. Systematic review and meta-analysis.
7. 7. A randomized trial of 50 mg oral DHEA for low libido in postmenopausal women. Journal of Sexual Medicine. 2009.
8. 8. DHEA supplementation and cognitive function in postmenopausal women. Systematic review. 2023.
9. 9. Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women. Meta-analysis of randomized controlled trials. 2025.
10. 10. Vaginal DHEA versus vaginal estradiol for dyspareunia and vulvovaginal atrophy. Randomized open-label trial. Maturitas. 2026.
11. 11. DHEA-S, Serum: Clinical and Interpretive. Mayo Clinic Laboratories.
12. 12. DHEA Sulfate Test. MedlinePlus.
13. 13. What athletes should know about DHEA. US Anti-Doping Agency.

Current commercial and access sources

1. 1. Official Intrarosa commercial savings information. Checked August 31, 2026.
2. 2. Official Intrarosa FAQ and insurance information. Checked August 31, 2026.
3. 3. Official Intrarosa Medicare savings program. Checked August 31, 2026.
4. 4. GoodRx Intrarosa pricing. Dynamic price observed August 31, 2026.
5. 5. Drugs.com Intrarosa price guide. Cash estimate observed August 31, 2026.
6. 6. Winona DHEA product page. Product, dose, price, support, refill, and cancellation claims checked August 31, 2026.
7. 7. Winona online menopause specialist state list. Checked August 31, 2026.
8. 8. Midi Health DHEA/estradiol cream. Product and price checked August 31, 2026.
9. 9. Midi Custom Rx store and FAQ. Cash-pay and insurance language checked August 31, 2026.
10. 10. Midi pricing and insurance. Visit prices checked August 31, 2026.
11. 11. Midi general 50-state virtual-care announcement. Product availability remains clinician- and pharmacy-dependent.

Reader-language sources

1. 1. Reddit discussion: OTC DHEA tablets versus Intrarosa. Used only for voice-of-customer language.
2. 2. Reddit discussion: low libido and DHEA uncertainty. Used only for voice-of-customer language.
3. 3. Reddit discussion: DHEA versus vaginal estrogen confusion. Used only for voice-of-customer language.

---

Editorial and affiliate disclosure: The HRT Index has affiliate relationships with some online menopause providers mentioned on this site, including Winona and Midi Health. Affiliate relationships never determine FDA status, evidence conclusions, the route judged to fit a symptom, or whether a provider receives a direct link. This guide contains no treatment-success testimonials, invented review scores, or fabricated clinical review.